Diuretic resistance risk and the efficacy of torsemide vs furosemide: a post-hoc analysis of the TRANSFORM-HF trial
Authors:
- 25 June 2026
- journal article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
Abstract
Background/Aims: Among hospitalized patients with heart failure (HF), diuretic resistance is associated with residual congestion, poor health status, and increased risk of HF hospitalization and mortality in the post-discharge period. The TRANSFORM-HF trial demonstrated no significant difference between torsemide and furosemide on clinical outcomes or quality-of-life following HF hospitalization. We assessed the association between diuretic resistance risk, assessed using the BAN-ADHF score, with risk of adverse outcomes among participants of the TRANSFORM-HF trial, and whether diuretic resistance risk modified the treatment effects of torsemide vs furosemide. Methods: This post-hoc analysis of TRANSFORM-HF included participants randomized to torsemide or furosemide who survived to discharge with available BAN-ADHF scores. High diuretic resistance risk was defined as BAN-ADHF score ≥12 during index hospitalization. Associations of diuretic resistance risk with 12-month all-cause mortality, all-cause hospitalization, and quality of life (KCCQ-CSS) were assessed using adjusted Cox models, and linear mixed-effects models, respectively. Treatment effect modification was assessed via interaction terms between randomized treatment and diuretic resistance risk status (high vs low). Results: Among 2421 participants (age: 65 years, 62.9% male), 512 (21%) had high diuretic resistance risk. High diuretic resistance risk was independently associated with increased risk of all-cause mortality (aHR[95%CI]: 1.79[1.45–2.21], P < .001), all-cause hospitalization (aHR: 1.34[1.15–1.55], P < .001), and lower 12-month KCCQ-CSS improvement (−3.4 points, P = .037). Diuretic resistance risk status did not modify the treatment effect of torsemide vs furosemide on all-cause mortality (Pinteraction = .54), all-cause hospitalization (Pinteraction = .74), or quality-of-life on follow-up (Pinteraction > .05 at each timepoint). Conclusion: Among patients discharged after HF hospitalization, higher diuretic resistance risk, assessed by the BAN-ADHF score, is associated with higher risk of mortality, HF hospitalization, and worse quality-of-life. Diuretic resistance risk status did not modify the treatment effects of torsemide vs furosemide.Keywords
This publication has 25 references indexed in Scilit:
- Diuretic Resistance and the Efficacy of Hydrochlorothiazide in Acute Decompensated Heart Failure: A Post-Hoc Analysis of the CLOROTIC TrialEuropean Journal of Heart Failure, 2025
- Adequacy of Loop Diuretic Dosing in Treatment of Acute Heart Failure: Insights from the BAN-ADHF Diuretic Resistance Risk ScoreThe American Journal of Cardiology, 2025
- Diuretic Efficiency of a Single Dose of Subcutaneous Versus Oral Furosemide After Heart Failure Hospitalization Across Diuretic Resistance Strata: A Pilot Randomized Controlled TrialEuropean Journal of Heart Failure, 2024
- Impact of Baseline Kidney Dysfunction on Oral Diuretic Efficacy Following Hospitalization for Heart Failure – Insights from TRANSFORM-HFEuropean Journal of Heart Failure, 2024
- Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart FailureJAMA, 2023
- Validation Of The BAN-ADHF Risk Score And Risk Of Long-term Mortality In Patients With Acute Decompensated Heart FailureJournal of Cardiac Failure, 2022
- Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical CareJACC, 2020
- Diuretic Resistance in Heart FailureCurrent Heart Failure Reports, 2019
- Potential Advantages of Torsemide in Patients with Heart Failure: More than Just a ‘Water Pill’?European Journal of Heart Failure, 2017
- Dominance of Furosemide for Loop Diuretic Therapy in Heart FailureJACC, 2013